Barclays raised the firm’s price target on Exact Sciences (EXAS) to $75 from $55 and keeps an Overweight rating on the shares. The firm says Exact Sciences’ momentum continues to build following the “beat/raise” quarter.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EXAS: